These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17934364)

  • 41. Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura.
    Aledort LM; Salama A; Kovaleva L; Robak T; Newland AC; Nugent DJ; Brenner B; Zenker O;
    Hematology; 2007 Aug; 12(4):289-95. PubMed ID: 17654054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of acute immune thrombocytopenic purpura.
    Tarantino MD; Goldsmith G
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):28-35. PubMed ID: 9523747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnosis and management of primary immune thrombocytopenia in adults.
    Ejaz A; Radia D
    Br J Hosp Med (Lond); 2019 Apr; 80(4):C54-C57. PubMed ID: 30951423
    [No Abstract]   [Full Text] [Related]  

  • 45. [Clinical course, diagnostic and therapeutic management of immune thrombocytopenic purpura in children].
    Mitura-Lesiak M; Filiks-Litwin B; Malek U; Kowalczyk JR
    Med Wieku Rozwoj; 2004; 8(4 Pt 1):1004-11. PubMed ID: 15951618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors and predictors of treatment responses and complications in immune thrombocytopenia.
    Ong SY; Tan CW; Ramya V; Malik AA; Lee XH; Hwang JCC; Yang Y; Ng HJ; Lee LH
    Ann Hematol; 2021 Mar; 100(3):645-651. PubMed ID: 33515047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Adult autoimmune thrombocytopenia: diagnosis and treatment].
    Lechner K; Weltermann A; Pabinger I
    Wien Klin Wochenschr; 2006 May; 118(9-10):255-64. PubMed ID: 16810482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Twenty years experience with treatment of idiopathic thrombocytopenic purpura in a single department: results in 490 cases.
    Schiavotto C; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):22-8. PubMed ID: 8039754
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
    Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
    Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of chronic immune thrombocytopenic purpura in children and adults.
    Blanchette V; Freedman J; Garvey B
    Semin Hematol; 1998 Jan; 35(1 Suppl 1):36-51. PubMed ID: 9523748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura?
    Navez J; Hubert C; Gigot JF; Navez B; Lambert C; Jamar F; Danse E; Lannoy V; Jabbour N
    Platelets; 2015; 26(6):573-6. PubMed ID: 25275667
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency.
    Al-Ahmad M; Al-Rasheed M; Al-Muhani A
    J Investig Allergol Clin Immunol; 2010; 20(3):259-62. PubMed ID: 20635793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting response to splenectomy in children with immune thrombocytopenic purpura.
    Wood JH; Partrick DA; Hays T; Ziegler MM
    J Pediatr Surg; 2010 Jan; 45(1):140-4; discussion 144. PubMed ID: 20105594
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with high dose dexamethasone in the treatment of chronic symptomatic immune thrombocytopaenia.
    Van Riet FA; Wessels G; Hesseling PB
    East Afr Med J; 1999 Oct; 76(10):571-4. PubMed ID: 10734508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N; Evangelista ML; Amadori S; Stasi R
    Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mortality in severe, non aggressively treated adult autoimmune thrombocytopenia.
    Sailer T; Weltermann A; Zoghlami C; Kyrle PA; Lechner K; Pabinger I
    Hematol J; 2003; 4(5):366-9. PubMed ID: 14502264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.
    Bussel JB; Lee CS; Seery C; Imahiyerobo AA; Thompson MV; Catellier D; Turenne IG; Patel VL; Basciano PA; Elstrom RL; Ghanima W
    Haematologica; 2014 Jul; 99(7):1264-71. PubMed ID: 24747949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The epidemiology of immune thrombocytopenic purpura.
    Fogarty PF; Segal JB
    Curr Opin Hematol; 2007 Sep; 14(5):515-9. PubMed ID: 17934361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.